SAIZ price

SAIZ

SAIZ is a blockchain-based cryptoasset focused on financing the commercialization of oral antibody technology for infectious disease treatment. The project combines a utility token with a commercial licensing model involving BioLumen and LOA BIO PHARM, with an initial focus on oral antibody products for rotavirus in India, Thailand, and South Korea.

The SAIZ ecosystem is built around oral antibody technology based on IgY antibodies. According to the project, the technology is designed to provide antibodies in an orally administered format and is intended to reduce some of the logistical requirements associated with injectable treatments, including cold-chain storage and administration by medical personnel. LOA BIO PHARM is identified as a supplier of antibody raw materials and provides ceramic IgY production technology used within the project’s stated product ecosystem.

A licensing agreement between BioLumen and LOA BIO PHARM covers commercial rights for a standardized rotavirus oral antibody across India, Thailand, and South Korea. SAIZ states that commercial royalties generated from licensed products are intended to support the project ecosystem. The project’s roadmap includes regulatory submissions and commercialization activities, with regulatory approval and market availability remaining subject to applicable healthcare and pharmaceutical requirements.

The SAIZ token is a CNX-20 utility token with a stated fixed total supply of 50,000,000 SAIZ. The project describes several intended utilities for the token, including staking, ecosystem participation, payments, and governance. Staking rewards are described as being funded through royalties associated with the underlying licensing arrangement rather than through additional token issuance. The project also states that SAIZ holders will have governance rights covering areas such as partner approvals, exchange listings, treasury deployment, and ecosystem development.

SAIZ includes a payment component through the Copay card, which is designed to allow token holders to use SAIZ for payments at participating merchants within the Copay network. The project also identifies Happy Blockchain Academy (HBA) as its education and community component, with activities focused on blockchain education and ecosystem development across Asian markets and planned expansion into additional regions.

The project uses a progressive governance model. Its roadmap describes the introduction of on-chain community voting and a transition toward a full DAO structure, with the SAIZ Foundation planned as an independent oversight organization. The stated roadmap covers token launch and licensing, market entry and regulatory activities, ecosystem expansion, additional exchange listings, and broader international development.

SAIZ’s initial commercial focus is on India, Thailand, and South Korea, while its longer-term roadmap includes expansion into other markets. The project’s development depends on pharmaceutical regulatory approvals, commercialization of the underlying antibody products, licensing arrangements, market adoption, and execution of its blockchain ecosystem plans.

The SAIZ token was launched as part of the project’s 2026 roadmap and is listed on Cofinex. The project identifies the token as a utility asset within its broader ecosystem rather than solely as a trading instrument. Future development is subject to regulatory requirements, commercial execution, technology development, and the successful implementation of the project’s stated partnerships and roadmap.